Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on April 21, 2021. The report discloses the entry into a material definitive agreement regarding the commercial supply of the company's pharmaceutical product, DSUVIA® (sufentanil).
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
On April 21, 2021, AcelRx entered into a Commercial Supply Agreement (CSA) with Catalent Pharma Solutions, LLC, effective March 31, 2021. Key terms include:
- Scope: Catalent will provide processing and packaging services for the single-dose applicator containing the 30 mcg sufentanil dosage form of DSUVIA.
- Term: The agreement lasts for five years from the "Commencement Date" (FDA approval of Catalent as a packaging manufacturer), with automatic two-year extensions unless terminated with 24 months' prior notice.
- Payment Structure:
- Monthly facility fees are payable prior to the Commencement Date.
- An annual fee begins the month following the Commencement Date.
- AcelRx will purchase 10-pack cartons at an agreed price through December 31, 2022.
- Pricing Adjustments: Pricing and fees (excluding raw materials) may be adjusted annually starting January 1, 2023. Raw material price increases will be passed through to AcelRx.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of general risks. The primary contingency noted is the "Commencement Date," which is dependent on FDA approval of Catalent as a packaging manufacturer. The full text of the CSA is referenced as an exhibit to be filed in the subsequent Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the exact "Commencement Date" once FDA approval for Catalent is granted, as this triggers the five-year term and annual fees.
- Review the full Commercial Supply Agreement in the upcoming Form 10-Q for specific pricing details and termination clauses.
- Monitor the impact of raw material cost pass-throughs on future gross margins.
- Confirm the status of DSUVIA commercialization and sales volume to assess the utilization of the new supply capacity.